Johnson & Johnson MedTech, the medical technology arm of Johnson & Johnson (J&J) on Thursday said the U.S. Food and Drug Administration (FDA) has approved an expanded indication for its TRUFILL n-BCA Liquid Embolic System. The device is now cleared for embolization of the middle meningeal artery (MMA) as an adjunct to surgery in the treatment of symptomatic subacute and chronic subdural hematoma (cSDH).
The approval is supported by the MEMBRANE study, which evaluated the safety and effectiveness of MMA embolization in patients with cSDH. The study found that TRUFILL n-BCA was more effective than standard of care for MMA embolization in treating symptomatic cSDH, while demonstrating a favorable safety profile.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.